MetaCap

Propanc Biopharma Inc. (PPCB)

NASDAQ: PPCBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.78+0.055 (+3.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PPCB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$95.92
52-week range
1.61 – 315.00
Day range
1.77 – 2.00
Volume / Avg
27.83K / 188.66K
Beta
—

52-week range

$1.61$315.00

PPCB stock today

On Nov 20, PPCB ended the session at $1.78, adding $0.055 (3.19%), versus the S&P 500's 3.70% decline. Trading was light, with 27.83K shares changing hands, about 15% of the average daily volume. Shares are 99.4% below their 52-week high of $315.00 and 10.6% above the 52-week low of $1.61, near the bottom of the past year's range.

Propanc Biopharma has posted a net loss over the last twelve months (EPS of -$95.92), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Propanc Biopharma

Company profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. James Nathanielsz
Headquarters
Camberwell, VIC
Employees
2

Financial highlights

Full financials

Propanc Biopharma reported a net loss of $18.9 million, compared with a loss of $58.9 million a year earlier. Diluted earnings per share came in at -$17.62.

Propanc Biopharma annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue—————
Growth—————
Net income$-18.86M$-58.92M$-1.82M$-2.66M$-2.66M
EPS (diluted)$-17.62$-371.22$-1,420.53$-1.80$-49.23

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-12.22 vs —

PPCB news

All PPCB news

Propanc Biopharma peers

Health Care sector
PPCB peer companies
CompanyPrice% ChgMarket capCompare
SBFMSunshine Biopharma Inc.2.23-5.11%$1.84Mvs PPCB
PPBTPurple Biotech Ltd. ADR1.53-4.09%$1.86Mvs PPCB
XRTXXORTX Therapeutics Inc.0.839-5.73%$1.88Mvs PPCB
EOCNEocene Ltd.1.78+1.73%$1.90Mvs PPCB
KALAKALA BIO Inc.2.71-10.28%$1.74Mvs PPCB
GNPXGenprex Inc.1.45-13.17%$1.94Mvs PPCB
DCOYDecoy Therapeutics Inc.0.8294-4.68%$1.98Mvs PPCB
REVBRevelation Biosciences Inc.3.50-5.15%$1.99Mvs PPCB

Indexes, lists and sector

Propanc Biopharma stock FAQ

What is Propanc Biopharma's stock price today?

PPCB last traded at $1.78 as of Nov 20, 4:00 PM EST, up 3.19% on the day. Prices are delayed at least 15 minutes.

Does Propanc Biopharma pay a dividend?

No. Propanc Biopharma does not currently pay a regular cash dividend.

Who is Propanc Biopharma's CEO?

Mr. James Nathanielsz is the chief executive officer of Propanc Biopharma Inc., which has about 2 employees.

Has PPCB ever split its stock?

Yes. The most recent PPCB stock split was a 1-for-10 split on Oct 26, 2026.

What is the PPCB 52-week high?

The 52-week high for PPCB is $315.00 and the 52-week low is $1.61. The stock is currently 99.4% below its high.

Compare PPCB